We're Getting Longevity Genetics Wrong. The Wellness Industry Already Knows It.

The finding from Dr. Ben Shenhar at the Weizmann Institute of Science is legitimate science: a reanalysis of Danish and Swedish twin registry data, applying a cleaner methodological filter than prior studies, produced a revised estimate that genetics accounts for approximately 55 percent of lifespan variation. That's a real result from a serious researcher at a credible institution. The problem isn't the science. The problem is the commercial infrastructure already waiting to exploit the number, and the communication norms that will hand it over with almost no resistance.

Within months of this kind of finding circulating in mainstream coverage, direct-to-consumer genetics companies will be citing a "55 percent genetic contribution to lifespan" in their marketing copy for longevity panels. That citation will be technically accurate and functionally misleading in ways that cause real harm.

Why the 55 % Figure Cannot Do What Marketers Will Ask It to Do

Heritability is a population statistic. It measures how much of the observable variation between people in a specific environment at a specific time is associated with genetic differences. It does not measure how genetically determined any individual's lifespan is. That distinction is not pedantic. It's the entire ballgame.

The researchers themselves flagged this directly. Shenhar noted that heritability figures shift as environments change: as 20th-century societies became safer and better vaccinated, the genetic component of lifespan variation grew in the twin data because fewer people were dying young from non-biological causes. Change the environment again, and the number moves again. A statistic that changes with the environment cannot tell you what your specific genome is doing to your specific aging trajectory. That's not a limitation that better technology will eventually fix. It's a structural property of what heritability measures.

Direct-to-consumer genetic tests face a compounding problem. Longevity is polygenic: shaped by hundreds or thousands of genetic variants, each with tiny individual effects. Shenhar's source data reviewed by earth.com noted that consistent genetic signals in longevity research are surprisingly rare, and when they do appear, they tend to tilt probabilities rather than determine outcomes. Current consumer-facing genetic panels don't capture this complexity. They identify a handful of variants, generate a risk score, and present it with an authority the underlying science doesn't yet support. Two centenarians can reach 100 in good cardiovascular health while carrying entirely different genetic combinations. No available test can reliably predict which pattern you carry, or whether you carry either.

The industry knows this. Companies that sell genetic longevity products are not misunderstanding the science. They're pricing uncertainty as a feature: the less the consumer knows about what the number means, the easier it is to sell them a subscription for ongoing testing, a supplement stack calibrated to their "genetic profile," or a premium tier that promises deeper analysis.

The Reasonable Defense: Imperfect Information Is Still Information

The strongest counterargument is that even partial genetic information is better than none, and that holding back any genetic insight pending perfect predictive tools sets an impossibly high bar. If a test shows you carry a variant associated with elevated cardiovascular risk, even with modest effect size, isn't it better to know than not to know?

That argument has real weight. Clinical geneticists use incomplete genetic information to make consequential decisions all the time, and those decisions improve outcomes. Family history, which is a rough proxy for genetic risk, has driven cardiology screening recommendations for decades with measurable benefit. Knowing something about your biology, even imprecisely, can motivate behavioral change that the epidemiology clearly supports.

The counterargument breaks down at the point of delivery, not the point of information. A clinician who tells you that your genetic risk profile suggests earlier lipid screening is working within a framework of medical interpretation, followup testing, and treatment options. A consumer genetics company that tells you the same thing and then offers you a personalized supplement for $49 per month is exploiting the appearance of that clinical framework without providing any of its substance. The difference isn't genetic information versus no information. It's accountable interpretation versus unaccountable marketing dressed in the language of personalized medicine.

The Cost of Letting This Continue Without Clear Communication Standards

There's no regulatory body currently equipped to police how heritability statistics get used in consumer health marketing. The FDA's authority over genetic tests is narrow and contested. The Federal Trade Commission can act on provably false claims but struggles with claims that are technically accurate yet systematically misleading. A company that says "genetics accounts for over half of lifespan variation, and our panel tests key longevity variants" hasn't said anything false. It has implied a predictive capability it doesn't have.

The cost accumulates in two directions. Some people who get back a reassuring genetic report will reduce their engagement with the modifiable risk factors that still govern the other 45 percent of lifespan variation: the inflammation that diet influences, the cardiovascular stress that exercise addresses, the sleep quality that affects cognitive aging. Shenhar was explicit that lifestyle remains critical, but that nuance rarely survives the marketing funnel. Other people, particularly those with lower health literacy or less access to clinical context, will spend money on products calibrated to a genetic readout that doesn't mean what the product implies it means.

Good science published into a broken communication environment doesn't stay good science for long. It becomes a source for the following year's marketing campaigns, stripped of its methodological caveats, deployed with exactly the authority those caveats were designed to limit.

The 55 percent figure deserved careful, contextualized coverage. It's getting some of that in science publications. What it will get next, in consumer health channels, is a different story, and we should say so clearly before it arrives.

This is the kind of take we publish every week at The Science Impact: positions backed by evidence, not by consensus. Subscribe free. Read science with a sharper eye.